Erysipelas

disease
On this page

Summary

Erysipelas (MONDO:0001266) is a disease and 9 clinical trials. Top therapeutic interventions include amoxicillin, penicillin v, and floxacillin. A subtype of skin infection — broader associated-gene and molecular evidence is on the parent page (see Disease family below).

At a glance

  • Clinical trials: 9

Clinical features

No curated clinical features (Orphanet) for this disease.

Identifiers

Disease identifiers

FieldValue
Canonical nameerysipelas
Mondo IDMONDO:0001266
EFOEFO:1001462
MeSHD004886
DOIDDOID:11330
ICD-10-CMA46
ICD-111651247891
SNOMED CT44653001
UMLSC0014733
MedGen41855
Is cancer (heuristic)no

Data availability: 1 HPO phenotype.

Disease family

This is a subtype of skin infection. Genetic, therapeutic, and trial evidence is largely curated at the broader-term level — see the parent page for the associated-gene cohort and molecular evidence.

Classification path: disease › human disease › disease by body system or component › integumentary system disorder › skin disorderdermatitisskin infectionerysipelas

Related subtypes (13): cercarial dermatitis, cutaneous diphtheria, Pthirus pubis infestation, scabies, impetigo, herpes simplex dermatitis, gonococcal keratitis, tinea infection, herpes zoster dermatitis, infection by Trypanosoma gambiense, Demodex folliculitis, furunculosis, sycosis barbae

Genetics & variants

GWAS landscape

No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.

Variant details and genetic-evidence tiers

No tiered GWAS variants or ClinVar records for this disease.

Genes & proteins

No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).

Function

No pathway enrichment — requires an associated-gene cohort.

Therapeutics

No druggable-target or therapeutic data for this disease’s cohort.

Clinical trials & evidence

Clinical trials

Clinical trials: 9.

Phase distribution (across all retrieved trials)

PhaseTrials
PHASE44
Not specified3
PHASE22

Top trials by phase / activity

NCTPhaseStatusTitle
NCT07104552PHASE4NOT_YET_RECRUITINGComparing Short to Standard Amoxicillin Course for Erysipelas
NCT07549594PHASE4NOT_YET_RECRUITINGProphylaxis of Recurrent Erysipelas in Lower Limbs: compreSsion thErapy vs aNTibiotics and Compression Therapy.
NCT01059123PHASE4TERMINATEDShort Course of Amoxicillin for Erysipelas
NCT02032654PHASE4TERMINATEDDuration of ANtibiotic Therapy for CEllulitis
NCT00893048PHASE2WITHDRAWNThe Use of Oral Steroids in the Treatment of Cellulitis
NCT01519778PHASE2COMPLETEDA Phase 2 Safety and Exploratory Skin Lesion Measurement of TR-701 FA Study
NCT05360914Not specifiedRECRUITINGHospital at Home for Elderly Acute Ill Patients
NCT02902822Not specifiedCOMPLETEDTele-dermatology of Skin Cancer in a Cohort of Local Health Authority Employees in the Province of Bergamo
NCT03917277Not specifiedUNKNOWNMusculoskeletal Ultrasound of the Ankles in Erysipelas-like Erythema of Familial Mediterranean Fever

Drugs tested across these trials (top 30)

MoleculeMax phaseTrials referencing
AMOXICILLIN41
PENICILLIN V41
FLOXACILLIN31